Originally published by our sister publication Clinical Oncology News
By Kate O'Rourke
The FDA has approved elacestrant (Orserdu, Stemline Therapeutics) for postmenopausal women or adult men with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.
The agency also approved the Guardant360 CDx assay as a companion diagnostic device to identify patients with breast cancer for